Timothy Blecha, MD
Family Medicine · Superior, NENPI 1790777936
Payments from drug & device makers
Across 256 payments — averaging $13.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$850
- AbbVie$646
- Otsuka America Pharmaceutical, Inc.$403
- Novo Nordisk$323
- Pfizer$271
- Lilly USA, LLC$152
- plus $848 from 24 others
What the payments were for
- Food & beverage$3,493100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 69 | $850 |
| AbbVie(2 entities) | 48 | $646 |
| Otsuka America Pharmaceutical, Inc. | 21 | $403 |
| Novo Nordisk | 22 | $323 |
| Pfizer | 27 | $271 |
| Lilly USA, LLC | 15 | $152 |
| Johnson & Johnson | 8 | $121 |
| Gilead | 7 | $112 |
| Astellas Pharma US Inc | 7 | $108 |
| Lundbeck LLC | 4 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Abbott | 2 | $44 |
| AstraZeneca | 3 | $35 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Boston Scientific | 1 | $22 |
| Melinta Therapeutics, LLC | 2 | $22 |
| Optinose US, Inc. | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Osiris Therapeutics Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Novartis | 1 | $13 |
| Biocryst US Sales Co., LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$3,493 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $180,087 |
| EliquisApixaban | 197 | $145,879 |
| JardianceEmpagliflozin | 197 | $126,407 |
| FarxigaDapagliflozin Propanediol | 128 | $94,985 |
| Humira PenAdalimumab | 13 | $91,820 |
| XareltoRivaroxaban | 126 | $77,653 |
| TrulicityDulaglutide | 50 | $50,784 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 105 | $33,524 |
| InvokanaCanagliflozin | 38 | $22,789 |
| Repatha SureclickEvolocumab | 38 | $20,953 |
| EntrestoSacubitril/Valsartan | 32 | $19,716 |
| MyrbetriqMirabegron | 40 | $15,461 |
| LinzessLinaclotide | 32 | $15,304 |
| RybelsusSemaglutide | 14 | $14,636 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $323 | $194,723197 claims |
| PfizerEliquis, Abrysvo | $271 | $179,402302 claims |
| Boehringer IngelheimJardiance | $12 | $126,407197 claims |
| Johnson & JohnsonXarelto, Invokana | $121 | $100,442164 claims |
| AstraZenecaFarxiga | $35 | $94,985128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $152 | $61,90061 claims |
| NovartisEntresto | $13 | $19,71632 claims |
| Astellas Pharma US IncMyrbetriq | $108 | $15,46140 claims |
| AbbVieLinzess | $646 | $15,30432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Superior
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.